Summary
The claims are about pricing/cost drivers and affordability, which are not addressed in the provided FDA prescribing information excerpts. Therefore, all claims are unsupported by the label.
Category Scores
Accurate Statements
Unsupported Statements
Spironolactone prices vary mostly by tablet strength.
Pricing variability by tablet strength is not supported in the provided FDA label excerpts.
Spironolactone prices vary based on whether the buyer is purchasing a brand or generic.
Brand vs generic price differences are not addressed in the provided FDA label excerpts.
Spironolactone prices vary based on the number of tablets in the package.
Package quantity/cost scaling is not addressed in the provided FDA label excerpts.
Spironolactone prices vary based on the pharmacy and insurance/cash plan.
Pharmacy/insurance/cash plan pricing factors are not addressed in the provided FDA label excerpts.
Generic spironolactone tends to cost far less than brand-name versions.
Relative cost between generic and brand formulations is not supported in the provided FDA label excerpts.
Generic spironolactone is usually one of the more affordable options in its class for most patients.
Affordability ranking across a drug class for most patients is not addressed in the provided FDA label excerpts.
Multiple manufacturers produce generic spironolactone.
Number of manufacturers producing generics is not addressed in the provided FDA label excerpts.
Out-of-pocket cost for spironolactone can change depending on prescription quantity.
Out-of-pocket cost drivers (e.g., quantity) are not addressed in the provided FDA label excerpts.
Out-of-pocket cost for spironolactone can change depending on local pharmacy charges.
Local pharmacy charge effects on out-of-pocket cost are not addressed in the provided FDA label excerpts.
Spironolactone is an older, widely generic medicine.
Recency/age of the medicine and extent of generic availability are not addressed in the provided FDA label excerpts.
Patent-driven pricing pressure is usually not the main driver of spironolactone cost the way it can be for newer drugs.
Economic/patent-driven pricing assertions are not addressed in the provided FDA label excerpts.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims relate to pricing and affordability rather than dosing, safety, contraindications, or clinical use. While unsupported by the provided prescribing information, they do not directly introduce label-inconsistent medical instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All statements are about pricing/affordability and are not supported by the provided FDA-approved prescribing information excerpts.
Suggested Improvement
Remove or qualify pricing/affordability claims; if the goal is clinical label alignment, restrict content to label-supported information (indications, dosing, contraindications, warnings/precautions, interactions, and relevant patient populations).